1. Introduction {#s0010}
===============

Since the demonstration of RNA interference (RNAi) in mammalian model systems, much interest has arisen in the utilization of various promoters of RNAi, such as short-interfering RNA (siRNA) and micro-RNA (miRNA), for the treatment of diseases. RNAi is an endogenous process in eukaryotic cells that uses RNA molecules to catalyze degradation of specific, complementary messenger RNA (mRNA) sequences, possibly as a mechanism to protect against foreign pathogens such as viruses. When long double-stranded RNA is introduced into cells, a large, 200-kDa nuclease of the RNaseIII family known as Dicer ([@bib44]) cleaves the RNA into shorter fragments of approximately 21--23 nucleotides long. These fragments, or short-interfering RNA (siRNA) ([@bib18]), are then loaded into the RNA-induced gene silencing complex (RISC) ([@bib119]), a complex comprising many different proteins. One of these proteins is Argonaute 2 (Ago2), which is responsible for unwinding the siRNA and degradation of the sense or passenger strand ([@bib101]; [@bib120]). The single-stranded antisense strand then allows the RISC complex to actively seek out mRNA complementary to the antisense strand of the siRNA ([@bib6]). Once the mRNA is bound to the antisense strand of the siRNA, Ago2 mediates the cleavage of the mRNA between nucleotides 10 and 11 from the 5′ end of the antisense strand ([@bib149]). The RISC complex can then seek out and degrade additional mRNA, leading to remarkable silencing of the target gene ([@bib65]).

In theory, siRNA is able to specifically block the synthesis of any protein responsible for any disease; however, the actual translation of siRNA into clinical use has been hampered by several major difficulties. These include the need to protect siRNA from degradation by nucleases in biological fluids, the delivery of siRNA to target tissues, and the intracellular delivery of siRNA to the target cell's cytoplasm where RNAi takes place. Lipid nanoparticles (LNPs) are the leading delivery systems for enabling the therapeutic potential of siRNA for systemic applications ([@bib130]; [@bib168]). LNP-siRNA systems containing optimized ionizable cationic lipids exhibit remarkable in vivo potencies in silencing liver (hepatocyte) target genes at doses as low as 0.005-mg siRNA/kg body weight following intravenous (i.v.) injection in rodents ([@bib69]; [@bib130]). With therapeutic indices in mice approaching 1000, these systems are relatively nontoxic and demonstrate promising clinical utility. Here we review the challenges in siRNA delivery and different strategies to deliver siRNA, with a focus on LNP systems and their formulation methods. We also discuss the current LNP-siRNA formulations in clinical testing. It is important to note that technologies for the production of LNP systems are not restricted for siRNA but are also applicable to plasmid DNA, mRNA and potentially, clustered regularly interspaced short palindromic repeat (CRISPR) DNA. This versatility would not only pave the way for the translation of nucleic acid-based therapeutics into the clinic but would also expand our current arsenal of nucleic acid therapeutics.

2. Challenges and Strategies for Delivery of siRNA {#s0015}
==================================================

Delivery of siRNA for therapeutic purposes is hampered by several major hurdles. First, "naked" siRNA is unstable and rapidly degraded by nucleases in biological fluids ([@bib29]; [@bib83]). It has been shown that chemical modifications of nucleic acids, such as 2′ *O*-methyl ([@bib138]), 2′ fluoro-pyrimidine ([@bib117]), and phosphothioate linkages ([@bib30]) can protect siRNA from nuclease degradation. Second, siRNA cannot penetrate the cell membrane to enter the cytoplasm due to its large size, which ranges from 13 to 15 kDa, and negative charges ([@bib37]; [@bib156]). Moreover, despite evidence that naked siRNA can be taken up by endocytosis in neuronal cells, it faces an additional challenge of escaping the endocytosis-based degradation to mediate effective RNAi ([@bib90]). Finally, systemically administered siRNA accumulates in the liver and kidney and fails to accumulate at the site of disease ([@bib22]). As the glomerular filtration pore size is roughly 8 nm, naked siRNA are removed from circulation by the kidneys and excreted ([@bib64]). Delivery vehicles are therefore necessary to overcome the above hurdles and realize the potential of siRNA as a therapeutic.

2.1. Localized Delivery of siRNA {#s0020}
--------------------------------

Despite these challenges, accumulating evidence suggests that siRNA can be delivered locally to some tissues without the use of a sophisticated delivery system. One of the simplest strategies by which to administer unprotected, free siRNA for therapeutic purposes is directly to the localized tissue. It has been shown that intranasal administration of free siRNA against the P protein of the respiratory syncytial virus (RSV) and parainfluenza virus localizes siRNA to the lungs for up to 2 days and inhibits subsequent infections by these two viruses ([@bib20]). Furthermore, the siRNA shows effective antiviral properties when administered after RSV infection, with the best therapeutic response observed when the siRNA is administered at the time of viral infection ([@bib20]). Notably, the antiviral effects of this siRNA when complexed to the transfection reagent TransIT-TKO (Mirus Bio, Madison, WI) were significantly better than that of the naked form. A chemically modified siRNA targeting the nucleocapsid protein of RSV for intranasal delivery has since been developed by Alnylam Pharmaceuticals (Cambridge, MA). The siRNA formulation, named ALN-RSV01, was effective in inhibiting RSV when administered either prophylactically or therapeutically ([@bib5]). In a phase II clinical trial, ALN-RSV01 was demonstrated to be safe and provided modest protection against RSV infection compared to placebo treatment ([@bib38], [@bib39]). Another example of clinical applicability is the intranasally administered siRNA against the SARS coronavirus, which was shown to alleviate SARS-like symptoms in rhesus macaque ([@bib91]).

The eye is another popular tissue for local administration of siRNA. Age-related macular degeneration is a disease characterized by the development of choroidal neovascularization (CNV) in the eye. Intravitreal injection of naked siRNA against the vascular endothelial growth factor (VEGF) receptor has been shown to decrease the extent of CNV in mice ([@bib133]). The siRNA was localized in the ganglion layer of the retina by 6 h after injection and the mRNA levels of VEGF receptor were significantly reduced by 7 days after injection. An intravitreal dose of as low as 0.5 μg siRNA was enough to suppress the development of laser-induced CNV in mice ([@bib133]). In a similar study, intravitreal injection of siRNA targeting erythropoietin was effective at reducing neovascularization induced by hypoxia ([@bib25], [@bib26]). In a nonhuman primate model of laser-induced CNV, an intravitreal dose of 70-μg siRNA targeting VEGF suppressed the development of CNV for 36 days after laser induction ([@bib148]).

The presence of the blood-brain barrier makes it extremely difficult for drugs, especially large molecules such as siRNA, to reach the central nervous system from the blood compartment. Direct administration is therefore the preferred route of drug entry. It has been shown that siRNA can be directly administered through either the intraventricular or intrathecal route to mediate gene silencing in the brain. Intraventricularly injected siRNA has been shown to mediate the gene silencing of enhanced green fluorescent protein (EGFP), dopamine transporter and serotonin transporter in the brain ([@bib143], [@bib144]). Also, intrathecally administered siRNA targeting the pain-related cation channel P2X~3~ has been shown to reduce both P2X~3~ expression and pain perception in treated mice ([@bib40]).

Despite the successes in the above examples, many tissues in the body remain inaccessible by local administration. Systemic delivery of drugs to these tissues would require the use of an appropriate delivery system.

2.2. Strategies for Systemic Delivery of siRNA {#s0025}
----------------------------------------------

One of the simplest and earliest examples of systemic delivery of siRNA is the conjugation of cholesterol onto the 3′ end of the sense or passenger strand of the siRNA ([@bib137]). Intravenous administration of cholesterol-conjugated siRNA against apolipoprotein B (apoB) effectively decreased levels of apoB mRNA in the liver as well as plasma apoB protein and serum cholesterol ([@bib137]). Modifications such as 2′-*O*-methyl at the ribose and phosphothioate at the siRNA backbone offer general protection for the siRNA against hydrolysis by nucleases. Other modifications for siRNA are available and reviewed elsewhere ([@bib37]; [@bib76]; [@bib156]). The effective uptake of cholesterol-conjugated siRNA by hepatocytes is mediated via its association with serum lipoproteins ([@bib158]). Moreover, the reconstitution of cholesterol-conjugated siRNA into purified mouse high density lipoprotein (HDL) showed higher gene silencing efficacy than free cholesterol-conjugated siRNA ([@bib158]). Others also demonstrated that mimetic lipoprotein particles prepared from recombinant apolipoprotein A1 and apolipoprotein E3 can effectively deliver cholesterol-conjugated siRNA to the liver and mediate effective gene silencing ([@bib111]). These examples highlight the importance of endogenous lipoproteins in mediating the uptake of cholesterol-conjugated siRNA. Indeed, it was later revealed that LNP-siRNA also depends on the lipoprotein pathway for effective uptake in the liver ([@bib2]).

While cholesterol conjugation is a delivery strategy specifically designed for siRNA, most cationic polymers were initially used to deliver plasmid DNA or antisense oligonucleotides and later applied to siRNA. Polyethylenimine (PEI) is a polycationic polymer widely used for condensing nucleic acids into a transfection-competent polyplex ([@bib176]; [@bib178]; [@bib180]). It has been shown that polyplexes of PEI and siRNA targeting the *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor reduced the expression of the receptor and decreased pain perception in rats following intrathecal administration ([@bib142]). After administration of 5 μg of siRNA, significant reduction in NMDA receptor mRNA was observed in 3 days and protein levels of the NMDA receptor was suppressed for 14 days ([@bib142]). In addition to condensing nucleic acids, PEI has been shown to protect siRNA from degradation by serum nucleases ([@bib77]; [@bib97]; [@bib128]; [@bib151]). PEI has also demonstrated efficacy through other means of administration. Intravenous administration of polyplexes of PEI and siRNA against VEGF has shown intratumoural localization of the polyplexes as well as silencing of VEGF in mice ([@bib177]). In a xenograft mouse tumor model, intraperitoneal injection of PEI-siRNA targeting the HER2 receptor led to the downregulation of HER2 expression and inhibition of tumor growth ([@bib151]). Despite these successes, the toxicity of high molecular weight PEI, such as PEI87 (87 kDa) and PEI217 (217 kDa), remains a major hurdle for its clinical application ([@bib145]; [@bib146], [@bib145]; [@bib150]; [@bib169]).

Cyclodextrin polymer (CDP) is another popular cationic polymer used for the delivery of siRNA in vivo. Each cyclodextrin monomer comprises five to eight glucopyranose molecules linked together into a ring by α1 → 4 linkages ([@bib76]). These cyclodextrin monomers are then joined together by a linker containing cationic amidine groups, which bind nucleic acids including siRNA ([@bib49]). When mixed with plasmid DNA, CDP has been shown to self-assemble into a spherical complex of approximately 120 nm in diameter ([@bib49]; [@bib66]). Interaction of CDP particles with plasma components can be prevented by coating the particle surface with polyethylene glycol (PEG) conjugated to adamantane, which is a hydrophobic moiety that form an inclusion complex with cyclodextrin by inserting into the cyclodextrin core ([@bib35]). Targeting ligands, such as transferrin, can be coupled to the adamantane-PEG to target the CDP nanoparticle to specific cells ([@bib17]; [@bib35]). In a mouse model of Ewing's sarcoma, transferrin-adamantane-PEG CDP nanoparticles were able to reduce metastatic tumor size after three consecutive daily doses of 2.5 mg/kg siRNA ([@bib63]). Although no measurable innate immune response or toxicity in the liver and kidney was observed, tumor volume rebounded soon after cessation of treatment ([@bib63]). In another study, CDP nanoparticles also did not show significant signs of toxicity or innate immune response in cynomolgus monkeys at doses up to 9 mg/kg siRNA; however, kidney and liver damage as well as elevated levels of pro-inflammatory cytokines were observed at a siRNA dose of 27 mg/kg ([@bib60]). Finally, in a phase I clinical trial involving melanoma patients, CDP nanoparticles containing siRNA against the ribonucleotide reductase M2 subunit (RRM2) were effective at reducing both the mRNA and protein levels of RRM2 in tumors ([@bib36]). In addition to PEI and cyclodextrin, other synthetic polymers such as chitosan and poly(lactic-co-glycolic acid) are also under intensive investigation for their potential in siRNA delivery in vivo ([@bib116]; [@bib118]; [@bib165]).

In comparison to cationic polymers, lipid nanoparticles (LNP) are currently the most mature technology enabling the delivery of siRNA in vivo, with at least four formulations of LNP-siRNA in various phases of clinical trials for the treatment of hypercholesterolemia, transthyretin-mediated amyloidosis and liver cancers ([@bib4]). LNP exhibit potent gene silencing activity in hepatocytes at doses as low as 0.005 mg siRNA/kg body weight in mice and 0.03 mg siRNA/kg in nonhuman primates following a single i.v. injection ([@bib69]). This is approximately 1000 times more effective than the examples of PEI and cyclodextrin delivery systems mentioned above. Furthermore, recent clinical results indicate that LNP-siRNA systems provide prolonged suppression of human transthyretin at a single dose of 0.3 mg siRNA/kg body weight, with full recovery occurring by day 70, the current gold standard for potency of a siRNA-based drug ([@bib31]). The following sections will discuss various formulation methods for these leading edge delivery systems.

3. Lipid-Based Delivery Systems {#s0030}
===============================

Current development of the encapsulation technology for siRNA stems from early work on liposomes for small molecule delivery. In the early 1960s, Alec Bangham and colleagues realized that lecithin (egg yolk phosphatidylcholine) assembles into concentric lamellae when dispersed in water ([@bib12]). Later it was reported that these lipid vesicles are capable of maintaining a concentration gradient of ions, which can be disrupted by the addition of detergents ([@bib13]; [@bib14]). Studies on the properties of lipid vesicles intensified soon after its discovery and it was quickly realized that the physical properties of these vesicles such as osmotic swelling and ability to trap solutes including ions and glucose were qualitatively similar to that of the cell membrane ([@bib132]). These lipid vesicles were initially termed "Bangasomes" due to their discovery by Alec D. Bangham; however, the term "liposome" was adopted subsequently ([@bib132]). In one of the first applications of liposomes as model biological membranes, Bangham and colleagues demonstrated that liposomes exposed to anesthetics were more permeable to ions ([@bib73]). Subsequently, liposomes have been widely used as drug delivery vehicles.

3.1. Lipid Systems for Small Molecule Drugs {#s0035}
-------------------------------------------

The potential of the liposome as a drug carrier was recognized soon after its discovery in the early 1960s. Gregory Gregoriadis was one of the pioneers to recognize the drug delivery potential of liposomes and apply them in enzyme replacement therapy ([@bib51]; [@bib52]). These systems were made by hydrating the dry lipid film with an aqueous buffer containing the enzyme amyloglucosidase or albumin. The resulting encapsulation efficiency was extremely poor, with less than 10% of the original enzymes and proteins being encapsulated. Encapsulation of antibiotics such as penicillin and actinomycin was also very poor ([@bib50]).

The major breakthrough for improving drug encapsulation efficiencies in liposomes came with the development of the transmembrane pH gradient loading technique to entrap weakly basic drugs, which can be accomplished by three different methods ([Figure 4.1](#f0010){ref-type="fig"} ). First, a pH gradient is generated by hydrating the lipid film with a low pH buffer followed by a buffer exchange using a solution of neutral pH ([Figure 4.1(A)](#f0010){ref-type="fig"}). It was demonstrated that weakly basic compounds such as catecholamines can be concentrated inside liposomes with an acidic interior ([@bib112]). Later, it was shown that drugs that are weak bases, such as doxorubicin, could also accumulate in high amounts inside liposomes with an acidic interior ([@bib104]; [@bib105]). The encapsulation of drugs in response to a transmembrane pH gradient can be readily explained. At neutral pH, weakly basic drugs are a mixture of the protonated, membrane-impermeable form (DH^+^) and the deprotonated, membrane-permeable form (D). The deprotonated form of the drug (D) can readily diffuse across the membrane and then becomes protonated (DH^+^) and trapped inside the liposome where the pH is lower than the pK~a~ of the drug ([Figure 4.1(A)](#f0010){ref-type="fig"}). At equilibrium, the drug concentration gradient mirrors the proton gradient; thus a pH gradient of 3 units results in a 1000-fold higher drug concentration inside the liposome than that of the exterior medium. Figure 4.1Encapsulation of small molecule drugs in response to transmembrane pH gradient.(A) In the standard pH gradient method, the lipid film is first hydrated with buffer of low pH (typically citrate buffer, pH 4), followed by extrusion generating large unilamellar vesicles. A pH gradient is generated by exchanging the external buffer with a buffer of higher pH (typically HEPES, pH 7.5). Weakly basic drugs enter the vesicle in their neutral form and then become protonated and trapped in the acidic interior of the vesicle. (B) In the ammonium sulfate method, a transmembrane ammonium sulfate gradient is first generated by hydrating and extruding the lipid in a buffer containing ammonium sulfate, followed by an exchange of the external buffer. The interior of the vesicle is acidified as the neutral NH~3~ exits the vesicle, leaving behind a proton in the process. This pH gradient is then used for the encapsulation of weakly basic drugs. (C) In the ionophore method, a transmembrane gradient of Mg^2+^ or Mn^2+^ is first generated. The ionophore A23187 couples the export of Mg^2+^ with the import of two protons, therefore acidifying the interior of the vesicle. A chelator of Mg^2+^, such as EDTA, is usually required to remove the Mg^2+^ as it is transported out of the vesicle.

In the second method, the loading of weakly basic drugs can be accomplished using ammonium sulfate ([@bib21]). In this scenario, a pH gradient is generated by encapsulating ammonium sulfate inside the liposome followed by exchanging the external buffer ([Figure 4.1(B)](#f0010){ref-type="fig"}). An equilibrium of positively charged ammonium ion $\left( \text{NH}_{4}^{+} \right)$ and neutral ammonia (NH~3~) exists inside the liposome. Since the lipid membrane is highly permeable to the uncharged NH~3~, one proton remains inside the liposome as NH~3~ travels down its concentration gradient to the outside of the liposome, resulting in acidification of the liposome interior ([Figure 4.1(B)](#f0010){ref-type="fig"}). Loading of weak base drugs in response to pH gradient can result in interior drug concentrations that are so high that nanocrystals of drugs are formed, leading to a characteristic "coffee bean" appearance in electron micrographs ([@bib1]).

The use of an ionophore offers a third method to generate a pH gradient needed for the encapsulation of weakly basic drugs ([@bib43]). A transmembrane gradient of divalent cations such as Mn^2+^ or Mg^2+^ is first generated by preparing liposomes in solutions of MnSO~4~ or MgSO~4~ followed by an exchange of the external buffer with a sucrose solution. After generating the divalent cation gradient, the weakly basic drug, the ionophore A23187 and Ethylenediaminetetraacetic acid (EDTA) are added to the large unilamellar vesicle (LUV). The ionophore couples the transport of one divalent cation out of the LUV with the import of two protons, resulting in acidification of the vesicle interior ([Figure 4.1(C)](#f0010){ref-type="fig"}) ([@bib43]). The exported divalent cations are then chelated by EDTA while the drug enters the vesicles. This method showed very high levels of encapsulation (\>80%) for both vincristine and ciprofloxacin with drug retention properties similar to other pH gradient loading methods ([@bib43]).

The goal of using liposomes as drug delivery vehicles is to enhance the potency of drugs and reduce their side effects by increasing their delivery to the sites of disease while avoiding the healthy tissues. Many studies have noted that the vasculature at sites of disease such as tumors, sites of infection and sites of inflammation is "leakier" than that of healthy tissues ([@bib135]; [@bib140]). For example, the neovasculature formed in tumors lacks the smooth muscle wall of normal vasculature and is relatively permeable to particles of 200-nm diameter or larger ([@bib164], [@bib163]). As a result, long-circulating liposomes with a diameter of 100 nm preferentially escape in the region of tumors, resulting in large increases in the amount of drug that is delivered to the tumor. In addition, lymphatic drainage in the tumor is often impaired, causing liposomes to be retained in the interstitial space ([@bib95]). This combined phenomenon is called the enhanced permeation and retention (EPR) effect ([@bib95]; [@bib96]). It is important to note that the encapsulated drug is not available to target cells and must be released from the liposome to exert its effect. For certain drugs, the rate of drug release strongly influences the anticancer potency of the formulation. This is particularly true of cell cycle-specific drugs such as vincristine ([@bib106]; [@bib155]). To achieve optimal therapeutic activity, the rate of drug release can be controlled by changing the lipid composition of the liposome ([@bib24]) or by varying the drug-to-lipid ratio ([@bib74]).

Serum lipoproteins have been shown to play a critical role in both the circulation lifetime and cellular uptake of lipid nanoparticles. It has been shown that the apolipoproteins apoA-I, apoA-IV, and apoE bind to the surface of neutral phospholipid liposomes ([@bib19]). In particular, only apoE, but not apoA-I and apoA-IV, was shown to mediate cellular uptake of these liposomes by hepatocytes in vitro ([@bib19]). Similarly, apoE was shown to mediate hepatic uptake and blood clearance of neutral liposomes in vivo ([@bib162]). ApoE is an apolipoprotein found on the surface of cholesterol-enriched lipoproteins, such as chylomicrons, very-low density lipoproteins (VDLs) and high density lipoproteins (HDLs) ([@bib98]; [@bib99]). The uptake of these lipoproteins by hepatocytes is mediated by receptor-mediated endocytosis of low density lipoprotein (LDL) receptor, LDL receptor (LDLR)-related protein and scavenger receptor BI ([@bib15]; [@bib81]; [@bib99]). The role of apoE in mediating the hepatocellular uptake of LNP-siRNA system comprising ionizable cationic lipid was demonstrated in vivo with the use of ApoE-deficient mice ([@bib2]). The authors demonstrated that both ionizable LNP uptake by hepatocytes and silencing of the hepatic gene Factor VII were greatly reduced in ApoE-deficient mice compared to wild-type animals. The results were similar in *LDLR* ^*-/-*^ mice, which lack the LDLR to mediate hepatocellular uptake of the LNP. Interestingly, efficacy of LNP in ApoE-deficient mice can be rescued by conjugating the targeting ligand N-acetylgalactosamine (GalNAc) onto the PEG lipid of the LNP. GalNAc binds to the asialoglycoprotein receptor expressed on the surface of the hepatocyte with high affinity, providing an alternative pathway for LNP-siRNA to enter the hepatocytes of ApoE-deficient mice ([@bib2]). In contrast, LNP composed of a permanent positively charged cationic lipid does not seem to depend on apoE for liver uptake, and its gene silencing efficacy in vivo was lower than that of ionizable LNP ([@bib2]).

3.2. Lipid Systems for siRNA {#s0040}
----------------------------

Unlike the entrapment of soluble drugs in neutral liposomes, cationic lipids are essential for efficient encapsulation of nucleic acids; lipid formulations without cationic lipids result in poor encapsulation of antisense oligonucleotides ([@bib94]). The use of cationic lipid was first described by Felgner and coworkers ([@bib42]), who used the permanently positively charged cationic lipid, *N*-\[1-(2,3-dioleyloxy) propyl\]-*N*,*N*,*N*-trimethylammonium chloride (DOTMA) to mediate cellular transfection of DNA. The positive charges of cationic lipids facilitate the encapsulation of anionic nucleic acids via electrostatic interactions. Cationic lipids can also provide a positive surface charge to the LNP, promoting close association of the LNP with the negatively charged cell surface. It has been shown that cell surface proteoglycan and sialic acids interact with cationic liposomes and facilitate their cellular uptake via the endocytic pathway ([@bib107]; [@bib109]; [@bib139]; [@bib159]). Following endocytosis, cationic lipids of the LNP are hypothesized to form membrane disruptive ion pairs with anionic lipids of the endosomes, thereby facilitating intracellular release of nucleic acids ([@bib54]; [@bib55]). However, positively charged liposomes are rapidly eliminated by the mononuclear phagocyte system (MPS) ([@bib92]). Because most permanently charged cationic lipids are highly toxic, this has severely limited their in vivo application ([@bib8]; [@bib88]; [@bib128]; [@bib166]).

To avoid toxicity issues, ionizable cationic lipids with primary, secondary, or tertiary amines in the headgroup and apparent pK values of less than seven have been developed for the purposes of encapsulating nucleic acids when the lipid is positively charged at pH values below the pKa (e.g. pH 4), and for almost neutral LNP at physiological pH values. The first ionizable cationic lipid used for the encapsulation of nucleic acids was 1,2-dioleoyl-3-dimethylammonium propane (DODAP) ([@bib102], [@bib103]; [@bib131]) with a pKa of 6.6 ([@bib9]). Antisense oligonucleotides LNP containing DODAP exhibited a relatively long circulation lifetime following i.v. administration, as expected for a lipid particle with little surface charge ([@bib131]).

In the past several years, significant improvement in the potency of LNP-siRNA was achieved by varying the chemical structure of the ionizable cationic lipid. This is noted in [Figure 4.2](#f0015){ref-type="fig"} where the progression from DODAP to DODMA, DLinKDMA, DLinKC2DMA, and DLinMC3DMA is shown. These lipids were identified using an in vivo screening model employing LNP systems containing siRNA to silence Factor VII (FVII), one of the proteins in the blood-clotting cascade. Factor VII is made in hepatocytes and secreted into the circulation, thus the potency of the LNP-siRNA systems can be monitored by measuring FVII levels in the circulation 24 h after i.v. administration of the LNP. Remarkably, the potency of LNP-siRNA systems improved from ∼10 mg siRNA/kg body weight to result in 50% gene silencing for LNP containing DODAP to 0.005 mg siRNA/kg body weight for the LNP containing DLinMC3DMA ([@bib69]; [@bib130]). This improvement in potency is attributed to the use of ionizable cationic lipids with optimized pKa values and maximized bilayer destabilizing capabilities given the presence of anionic lipids that exist within the endosome. DLinMC3DMA, with a pKa of 6.4, is currently the most potent ionizable cationic lipid for hepatic gene silencing in vivo ([@bib69]).Figure 4.2Evolution of cationic lipids.Early cationic lipids, such as DOTMA and DODAC, contain a permanently positive quaternary amine headgroup. Ionizable cationic lipids with tertiary amines in the headgroup have an apparent pKa less than seven, which allowed encapsulation of nucleic acids to be performed at acidic pH (pH 4.0) while the resulting LNP will exhibit a net neutral charge at physiological pH.

The type of PEG lipid can also influence the potency of LNP-siRNA systems. PEG lipids are incorporated into LNP-siRNA formulations to prevent particle aggregation during the formulation process as the PEG moiety provides a hydrophilic steric barrier on the particle surface ([@bib102]; [@bib102], [@bib103]). Without the PEG-lipid coating, it is impossible to produce small LNP-siRNA systems with diameters of less than 100 nm, and large micron sized aggregates are instead formed. Although the PEG coating is important for forming small and stable particles, it can also inhibit LNP association with the plasma membrane of target cells, indicating a need to remove the coating before cellular uptake can proceed. One potential solution is to use acid-labile PEG lipids where the PEG moiety dissociates from the lipid anchor at low pH ([@bib28]; [@bib53]; [@bib134]). However, the pH required is too low (pH \< 5) to exist in the extracellular medium and thus the PEG lipids remain on the LNP surface, preventing close association with the cell membrane. Another approach is to use a PEG lipid that dissociates from the LNP in circulation following i.v. administration. The length of lipid chains anchored on the PEG lipid influences how long it stays on liposomes ([@bib115]), with longer acyl chains showing longer retention times than their shorter counterparts. Recently it has been shown that PEG lipids with short (C~14~) acyl chains dissociate from LNP-siRNA in vivo with a half-time of approximately 1 h ([@bib110]), whereas PEG lipids with longer (C~18~) acyl chains exhibit dissociation rates of days or longer. This offers the possibility of employing LNP stabilized by PEG lipids with short acyl chains that rapidly dissociate following i.v. administration, allowing the LNP-siRNA systems to become potent transfection agents.

In addition to cationic lipids and PEG lipids, LNP formulations of siRNA typically contain other structural lipids. The most commonly used lipids are cholesterol and a saturated phosphatidylcholine (PC) such as distearoyl-PC (DSPC) or dipalmitoyl-PC (DPPC). The reasons as to why these lipids are required are unclear. Cholesterol is included because of historical data for bilayer liposomal systems indicating that liposomes consisting of PC alone accumulate cholesterol from serum components ([@bib122]); consequently, systems containing approximately equimolar cholesterol are in better equilibrium with their surroundings. The need for DSPC is counter-intuitive as the presence of DSPC would be expected to mitigate against fusion with the endosomal membrane following uptake into target cells due to its strong bilayer-stabilizing properties ([@bib34]). However, recent data from our group suggested that elimination of DSPC compromises the gene silencing potency of LNP-siRNA systems for reasons yet to be determined (unpublished data).

There has been extensive work as well to incorporate targeting ligands into LNP systems. Targeting moieties such as antibody fragments and small molecule ligands have been coupled onto the surface of LNP in hopes of increasing cellular uptake of the LNP in target tissues through receptor-mediated endocytosis ([@bib4]; [@bib127]). It has been reported that liposomes with monoclonal antibody fragment against HER2 showed better cellular uptake in HER2-overexpressing breast cancer xenografts as compared to nontargeted liposomes ([@bib78]). Also, antibody-bearing liposomes containing antisense oligonucleotides against viral mRNA have showed better efficacy against viral infection compared to the same liposomes without the antibody ([@bib84]). In addition to using antibodies as the targeting moiety, small molecules have also been coupled to the PEG lipid for enhancing LNP uptake in cells and subsequent gene silencing activity. For example, anisamide, a small compound that interacts with the sigma receptors, increases gene silencing activity of siRNA nanoparticles in lung tumors and metastases ([@bib25], [@bib26]; [@bib89]; [@bib87]). In addition, we have shown that strophanthidin, a cardiac glycoside that binds to the ubiquitously expressed cell surface receptor Na^+^/K^+^ ATPase, enhances delivery of LNP-siRNA to cells originating from a number of tissues such as the prostate, ovary, breast, lung, and pancreas ([@bib141]). In many of these cases, the targeting moiety is conjugated to the distal end of the PEG lipid and the resulting targeting lipid is added along with the rest of the lipid components during the formulation process. Alternatively, the targeting lipid is added to the stable, preformed LNP in a process called postinsertion ([@bib67]). The use of postinsertion technique prevents the targeting lipid from interfering with the formulation process and provides a relatively simple method for preparing targeted LNP formulations.

3.3. Formulation Methods for LNP-siRNA {#s0045}
--------------------------------------

Similar to the development of cationic lipids, formulation technologies for siRNA were often designed for the delivery of plasmid DNA and later adopted for siRNA. The formulation used by Felgner and coworkers ([@bib42]) for cellular transfection was a simple mixture of DOTMA and dioleoyl-phosphatidylethanolamine (DOPE), which together form a complex (lipoplex) with plasmid DNA. Lipoplexes are often microns in diameter and are unstable and difficult to reproduce. They are often formulated with excess cationic charge not only to promote interaction with the plasmid DNA but also to facilitate association with the negatively charged cell surface and subsequent uptake by endocytosis ([@bib139]). Incorporation of helper lipids such as DOPE is thought to facilitate the release of plasmid DNA into the cytoplasm due to its propensity to adopt the nonbilayer, membrane lytic hexagonal H~II~ phase ([@bib33]). Despite intensive efforts, however, lipoplexes have not proven to be useful for in vivo applications. The chief reason for this shortcoming is that they are highly toxic due to their positive charge and are quickly removed from the circulation by the fixed and free macrophages of the MPS due to their size and charge. As a result, they do not distribute efficiently to target cells such as tumor cells.

These difficulties have led to attempts to encapsulate nucleic acids within an enclosed bilayer membrane that exhibits low surface charge. In the "stabilized antisense lipid particle" method, a solution of the lipids in ethanol is added to an aqueous solution of nucleic acid at pH 4.0 ([@bib131]). The relatively low pH of the buffer ensures that the ionizable cationic lipid, 1,2-dioleoyl-3-dimethylammonium propane (DODAP, pKa 6.6), is positively charged for interaction with the nucleic acid. The vesicles are subsequently extruded through polycarbonate membranes to ensure uniform size distribution. Dialysis in buffer at pH 7.0 removes residual ethanol in the mixture and deprotonates the ionizable cationic lipid, creating a relatively neutral system with prolonged circulation lifetimes ([Figure 4.3](#f0020){ref-type="fig"} ). Encapsulation efficiencies of over 70% and particle diameter of about 100 nm were achieved with this method ([@bib131]). Interestingly, the resulting particles are mainly unilamellar at a low nucleic acid-to-lipid ratio, but adopt a multilamellar configuration at higher nucleic acid-to-lipid ratios. These observations led to the suggestion that nucleic acid bridges between individual lipid vesicles promoting the formation of multilamellar structures.Figure 4.3Encapsulation of nucleic acid by the "stabilized antisense lipid particle" method.This method involves the dropwise addition of an ethanolic solution of lipids into an aqueous buffer containing nucleic acid. The drop in ethanol concentration facilitates the formation of vesicle as the ethanol concentration is now below the solubility limit of the lipids. The vesicles are subsequently extruded, followed by dialysis to remove residual ethanol and to raise the pH of the buffer. Encapsulation efficiencies are typically in the range of 70%. The resulting particles are approximately 80--140 nm in diameter and show a range of lamellarity, depending on the initial nucleic acid-to-lipid ratio.

A variation of the ethanol-drop method is the preformed vesicle (PFV) method ([@bib102], [@bib103]). PFVs containing DODAP, cholesterol, DSPC and a PEG lipid at low pH, typically pH 4, where the DODAP is protonated, are prepared by extrusion in the presence of up to 40% ethanol ([Figure 4.4](#f0025){ref-type="fig"} ). Extrusion is usually very rapid in the presence of ethanol. A solution of nucleic acid at pH 4.0 is then slowly added to the ethanol-destabilized liposomes to avoid particle aggregation and the mixture is then incubated for 1 h to allow encapsulation of the nucleic acid. Ethanol is removed by dialysis after the encapsulation step and the pH of the solution is adjusted to 7.0 to create a charge neutral system. This method generated multilamellar particles of approximately 100 nm in diameter with nucleic acid encapsulation efficiency of over 80% ([@bib102], [@bib103]). It was suggested that the attachment of nucleic acid onto the surface of the extruded liposome creates an adhesion point between liposomes, facilitating the formation of the multilamellar vesicles. This also explains the high nucleic acid encapsulation efficiency achieved with this method as the nucleic acid appears to be entrapped between lamellae of the multilamellar particle.Figure 4.4Encapsulation of nucleic acids by the preformed vesicle method.Lipid vesicles are first produced by dropwise addition of an ethanolic solution of lipids into an aqueous buffer, followed by extrusion. An aqueous solution of nucleic acid is added slowly to the resulting vesicle solution, which usually contains approximately 40% ethanol. The mixture is incubated for 1 h at 37 °C to allow encapsulation to take place. Residual ethanol is removed by dialysis and the pH of the solution is raised to 7.0. This method usually results in multilamellar particle of approximately 100 nm in diameter with an encapsulation efficiency of approximately 80%.

An alternative method to extrusion is the spontaneous vesicle formation (SVF) by ethanol dilution method ([@bib70]). Similar to many methods of encapsulation, this method was first developed for plasmid DNA and later adopted for the encapsulation of siRNA. In this method, nucleic acid is prepared in an acidic buffer, while cationic lipid, DSPC, cholesterol and PEG lipid are dissolved in ethanol. The nucleic acid and lipid mixtures are then combined using a T-tube mixer, with the flow of the two streams of fluid controlled via a peristaltic pump ([Figure 4.5](#f0030){ref-type="fig"} ) ([@bib70]). Vesicles form spontaneously as the lipids precipitate from solution as the polarity of the medium is raised. Residual ethanol in the final mixture is then removed by dialysis. For siRNA encapsulation, this method uses low amounts of PEG lipid, typically in the range of 1--5% (mol% lipid), and results in particles ranging from 70 to 80 nm in diameter ([@bib75]; [@bib168]). The encapsulation of siRNA is highly efficient with efficiencies of over 90% routinely achieved. The resulting LNP-siRNA are termed "stable nucleic acid lipid particles". Limitations of T-tube mixer formulation include the difficulty in applying the process to laboratory scale formulations due to the high flow rates needed to achieve rapid mixing, and the limited mixing rate which results in an inability to formulate LNP with lipid compositions that require very rapid mixing to achieve stable systems.Figure 4.5Encapsulation of nucleic acid with spontaneous vesicle formation by ethanol dilution.This method is also commonly referred as the "T-tube" method. It involves mixing of lipid components dissolved in ethanol with nucleic acid in aqueous buffer using a T-tube connector. The flow of the two streams of fluid is controlled with a peristaltic pump. Particles are formed as the ethanol is diluted below the solubility limit of the lipid. The ethanol content is further diluted upon exiting the T-tube connector to stabilize the resulting particles. Unencapsulated nucleic acid can be removed by using an ion exchange column. Residual ethanol is removed by diafiltration against phosphate buffered saline (PBS). This method has been used for encapsulation of plasmid DNA (stabilized plasmid-lipid particles), antisense oligonucleotides and siRNA (stable nucleic acid lipid particle).

The Cullis laboratory has developed an in-line mixing method employing a microfluidic herring-bone micromixer ([@bib16]). The herring-bone micromixer has two inlets, one for an ethanolic mixture of lipids and the other for a buffered solution of siRNA at pH 4.0. A dual syringe pump is used to drive the two streams of fluid into the herring-bone micromixer ([Figure 4.6](#f0035){ref-type="fig"} ). As the two streams of fluid meet at the herring-bone micromixer, they fold and wrap around each other, exponentially decreasing the diffusion length between the two streams. This allows for rapid mixing of the two streams of fluid on a millisecond timescale. The rapid decrease in solvent polarity results in the precipitation of lipids in accordance to their solubility. This technique has resulted in greater than 90% siRNA encapsulation efficiency over a wide range of siRNA-to-lipid ratios ([@bib85]). Cryo-transmission electron microscopy has indicated that LNP-siRNA produced by microfluidic mixing exhibit an electron dense core similar to the ones produced by T-tube in-line mixing ([Figure 4.7](#f0040){ref-type="fig"} ). Additional biochemical characterizations strongly suggest that the solid, electron dense core is comprised of distorted inverted micelles of cationic lipids complexed to the encapsulated siRNA. Furthermore, molecular dynamics simulation of LNP-siRNA systems suggests the particles contain a nanostructured, hydrophobic core with the siRNA surrounded by an inverted micelle of ionizable cationic lipids ([Figure 4.8](#f0045){ref-type="fig"} ). These results are consistent with the initial condensation of inverted micelles of ionizable cationic lipids around the siRNA, which serve as nucleating structures for the rest of the lipids to assemble into a solid core LNP ([Figure 4.9](#f0050){ref-type="fig"} ). The most hydrophilic lipid, the PEG lipid, would be the last component to be deposited on the nascent LNP thus providing an outer shell for the stabilized particle ([Figure 4.9](#f0050){ref-type="fig"}). The results are also consistent with the PEG lipid, as the last component to be deposited on the nascent LNP, providing the outer shell of the stabilized particle ([Figure 4.8](#f0045){ref-type="fig"}). Based on this model, one would expect the size of the resulting LNP to be dictated by the ratio of "core" lipid to "surface" lipid in the lipid mix. Indeed, the size of the particle is freely adjustable between 20 and 100 nm in diameter simply by altering the PEG-lipid content of the formulation ([@bib16]). In comparison with the PFV technique, microfluidic mixing results in higher encapsulation efficiency (\>90%), generates smaller particles, and permits small scale production with little loss due to dead volume. This method allows for well-defined and reproducible mixing between the solutions of lipids and siRNA, resulting in lower batch-to-batch variation ([@bib16]). Figure 4.6Encapsulation of siRNA by microfluidic mixing.This method employs a herringbone micromixer to facilitate the mixing of lipid components dissolved in ethanol and siRNA in aqueous buffer. The flow of the two streams of fluid is controlled using a dual syringe pump. The herringbone micromixer exponentially increases the surface area between the two streams of fluid, resulting in rapid mixing on a millisecond timescale. Residual ethanol is removed by dialysis and the pH of the solution is raised to 7.0. This method results in over 90% siRNA encapsulation efficiencies. Particle size is adjustable from 20 to 50 nm by varying the PEG-lipid content from 5% to 1%.Figure 4.7Cationic LNP produced by microfluidic mixing exhibit electron dense cores both in the presences and absence of siRNA as indicated by cryo-TEM.(A), Cryo-TEM micrograph obtained from siRNA-LNP with the lipid composition cationic lipid/DSPC/Cholesterol/PEG lipid (40/11.5/47.5/1; mol/mol) at a siRNA/lipid ratio of 0.06, wt/wt. (B), LNP with the same lipid composition as (A) but prepared in the absence of siRNA. (C), POPC/cholesterol (50/50; mol/mol) bilayer vesicles prepared by extrusion through polycarbonate filters with 80 nm pore size.Reproduced with permission from [@bib85].Figure 4.8A lipid nanoparticle (LNP) contains irregular water-filled cavities separated by bilayer membranes, with nucleic acids bound to the membrane surface.(A) side view, (B,C) cross-section, and (D) zoom-in views. Cationic lipid DLin-KC2-DMA is shown in yellow, cholesterol in pink, DSPC in grey, lipid polar moiety in cyan, PEG lipid in violet, nucleic acids (duplex DNA) in red, water not shown for clarity. The lipid composition was DLin-KC2-DMA/DSPC/cholesterol/PEG lipid (4:1:4:1; mol/mol) and DNA to lipid ratio ∼0.05 wt/wt. (For interpretation of the references to color in this figure legend, the reader is referred to the online version of this book.)Reproduced with permission from [@bib85].Figure 4.9Assembly of LNP-siRNA by microfluidic mixing.Lipid components reach their individual solubility limit and precipitate out of solution as the ethanol in the lipid stream is being diluted by the aqueous stream. The acidic sodium acetate buffer protonates the ionizable cationic lipids (blue), which then form an inverted micelle around the siRNA (red) via electrostatic interaction. As the polarity of the solvent increases, inverted micelles begin to aggregate, which is followed by coating by PEG lipids (purple) to form the LNP-siRNA. (See the color plate.)

The above-mentioned examples of formulation rely on ionizable cationic lipids to condense the siRNA for encapsulation into LNP. Alternatively, a lipid-coated calcium phosphate (LCP) nanoparticle that utilizes calcium phosphate to condense siRNA before encapsulation by a lipid layer was developed ([@bib86]). The fabrication process involves combining calcium chloride, sodium phosphate, and siRNA in a cyclohexane/Triton-X-100/hexanol solution to form a reversed-phase, water-in-oil micro-emulsion ([Figure 4.10](#f0055){ref-type="fig"} ). Aqueous sodium citrate is then added to the emulsion to form calcium phosphate precipitates with the entrapped siRNA. The calcium phosphate precipitate is then purified using silica gel and combined with liposomes made of the permanently charged cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and cholesterol to form the LCP nanoparticle ([Figure 4.10](#f0055){ref-type="fig"}). This LCP formulation was later modified to include the anionic lipid dioleoyl-phosphatidic acid (DOPA), which serves as an inner leaflet lipid to coat the calcium phosphate precipitate ([@bib93]). Electron micrographs of DOPA coated calcium phosphate showed a hollow core of approximately 20 nm in diameter. This is consistent with the hypothesis that the negatively charged DOPA headgroup interacts with the positively charged calcium phosphate core in a way that the acyl chains of DOPA face the exterior of the particle, forming an inverted micelle-like structure. The surface of the particle is then coated with a variety of surface lipids to adjust the surface charge of the final LCP from positive to negative. In addition, PEG lipids can be included to prolong the circulation lifetime of the resulting LCP nanoparticle ([@bib93]). siRNA encapsulation efficiency of the LCP nanoparticle is typically over 90% with a particle size of approximately 40 nm in diameter including the PEG coating ([@bib93]). An LCP nanoparticle constructed with the cationic lipid DOTAP and an anisamide targeting PEG lipid has demonstrated efficacy in inhibiting lung metastasis in a melanoma mouse model ([@bib161]). This nanoparticle contains three different siRNA sequences targeting MDM2, c-myc, and VEGF in order to achieve a greater therapeutic effect by inhibiting multiple pathways simultaneously. Mice treated with this targeted LCP particle have shown significantly improved survival rates and have markedly reduced numbers of lung metastatic nodules compared to either control mice or mice treated with LCP without the anisamide targeting ligand ([@bib161]). In addition, the LCP technology has been used to co-encapsulate siRNA with gemcitabine, a nucleoside analog used as a first-line chemotherapeutic for advanced non-small cell lung carcinomas ([@bib167]). The mechanism of action of LCP nanoparticle is still under investigation; however, it is hypothesized that the acidic environment inside the endosome dissolves the calcium phosphate core of these particles, which causes an increase in the endosomal osmotic pressure that eventually breaks the endosome and release the siRNA into the cytoplasm ([@bib86]). It is important to note that divalent cations such as calcium and magnesium are known to induce membrane-disrupting hexagonal H~II~ phases in membranes containing anionic lipids, such as the ones found in the endosomal membrane ([@bib62]; [@bib147]). It is possible that the calcium released from the LCP particle induces hexagonal H~II~ phases with anionic lipids of the endosomal membrane, thereby disrupting the integrity of the endosomal membrane and facilitating the intracellular release of the encapsulated siRNA.Figure 4.10Preparation of lipid-coated calcium phosphate (LCP) nanoparticle.This method consists of first preparing a solution containing calcium chloride and siRNA dispersed in a cyclohexane/Igepal oil, as well as a solution of dioleoyl-phosphatidic acid (DOPA) and sodium phosphate dibasic (pH 9) similarly dispersed in a cyclohexane/Igepal oil. These two solutions are then mixed for 20 min and the calcium phosphate cores containing the siRNA are isolated by centrifugation followed by a wash with ethanol. A mixture of outer lipids containing DOTAP, cholesterol and PEG lipid are added to the cores resuspended in chloroform. The chloroform is later removed by evaporation and the resulting LCP nanoparticle solution is resuspended in aqueous buffer.

4. LNP-siRNA Formulations in Clinical Trials {#s0050}
============================================

Recent advances in lipid-based formulation technologies have led to numerous LNP-siRNA formulations in various stages of clinical trials. One of the most advanced formulations is ALN-TTR02 from Alnylam Pharmaceuticals (Cambridge, MA), which is currently in a phase III clinical trial for the treatment of transthyretin (TTR) amyloidosis. In nonhuman primates, ALN-TTR02 was shown to cause a 75% decrease in serum TTR levels 7 days after a single i.v. dose of 0.1 mg siRNA/kg body weight ([@bib31]). For animals receiving a single 0.3 mg/kg dose of siRNA, over 70% suppression of serum TTR levels was observed for 28 days after LNP-siRNA injection. Similarly in humans, the authors observed 50% knockdown of TTR levels by day 3 after a single 0.3 mg/kg dose of siRNA and over 50% reduction in protein levels for 28 days ([@bib31]). The suppression of serum TTR levels by ALN-TTR02 was specific as siRNA targeting an unrelated protein had no effects on serum TTR levels. Furthermore, the formulation was well tolerated, with only minor infusion-related reactions and no liver and kidney toxicity.

Another promising formulation from Alnylam Pharmaceuticals is ALN-PCS, which is designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) produced by liver for the treatment of hypercholesterolemia. Mice lacking PCSK9 was shown to have increased expression of the LDLR in the liver and decreased levels of cholesterol in the plasma ([@bib121]). Knockdown of PCSK9 in nonhuman primates by LNP-siRNA was shown to lower serum LDL cholesterol levels and increase the expression of LDLR in the liver ([@bib46]). In a recent phase I clinical trial, a single dose of ALN-PCS at 0.4 mg siRNA/kg body weight caused a 70% decrease in serum PCSK9 levels 3 days after injection ([@bib45]). This has consequently resulted in a 40% reduction in serum LDL cholesterol level that required 30 days to recover to the pre-treatment level. Similar to the ALN-TTR02 formulation, ALN-PCS was well tolerated.

In addition to targeting intrinsic proteins of the body, the same LNP-siRNA technology is also actively pursued as a therapeutic against viral infections. Tekmira Pharmaceuticals (Burnaby, BC) has recently launched a Phase I clinical study for TKM-Ebola, an LNP-siRNA formulation for the treatment of infection from the Zaire strain of Ebola virus (ZEBOV). This formulation was produced using the T-tube in-line mixing technique mentioned above and contained three different siRNA sequences targeting the L polymerase, viral protein 24 and viral protein 35 of ZEBOV ([@bib47]). In a preclinical study utilizing nonhuman primates, all animals challenged with ZEBOV by intramuscular inoculation survived the infection following seven daily doses of TKM-Ebola at 2 mg siRNA/kg body weight per dose. The investigators were unable to detect ZEBOV in any of the treated animals after 14 days. Control animals treated with LNP-siRNA formulated with an unrelated siRNA against luciferase succumbed to the viral infection 10 days after viral inoculation. TKM-Ebola was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in March 2014.

Although LNP-siRNA systems are currently the most advanced siRNA delivery technology in clinical trials, lipoplexes of lipid and siRNA are also under active clinical investigations as means to deliver therapeutic siRNA in vivo. One such formulation is Atu027 from Silence Therapeutics GmbH (Berlin, Germany), a lipoplex formulation targeting protein kinase N3 (PKN3) for the treatment of advanced solid tumors ([@bib3]). This formulation contains a polycationic lipid, AtuFECT01, and is prepared by a method very similar to the PFV method described above ([@bib126]). One very important difference from the PFV method is the lack of ethanol during the formulation process. Ethanol is an important factor in facilitating the encapsulation of siRNA as it allows remodelling of PFVs into multilamellar vesicles after membranes are bridged together by electrostatic interactions with the siRNA ([@bib102], [@bib103]). Without the ethanol, the formulation is likely a complex of cationic liposomes linked together by siRNA on the surface. Regardless of the formulation procedure, Atu027 was effective at silencing PKN3 mRNA levels in the lung and liver of mice following tail vein injections of four daily doses of Atu027 at 0.7 mg siRNA/kg per dose ([@bib3]). The formulation was successful at reducing the volume of xenografted tumor in the prostate and lowering the amount of metastatic tumors in the lymph node of mice. The company is currently conducting Phase Ib/IIa clinical trials of Atu027 in combination with gemcitabine for the treatment of advanced pancreatic cancer. Interestingly, localization of Atu027 to the lungs following i.v. administration has prompted the company to develop a lipoplex formulation, DACC, to treat lung metastases ([@bib41]). Effective reduction of CD31 expression in lung tumors and an increased survival rate were observed in a mouse model of lung metastases injected via tail vein with DACC complexed with siRNA against CD31 ([@bib41]). It remains to be seen whether this formulation would be advanced to clinical testing for the treatment of lung metastases.

5. Future Prospects {#s0055}
===================

5.1. Avenues for Improving LNP Delivery {#s0060}
---------------------------------------

As mentioned above, tremendous efforts have been invested in the design of ionizable cationic lipids for maximizing the gene silencing capability of LNP-siRNA ([@bib69]; [@bib130]). Although hepatic gene silencing resulted from LNP-siRNA containing the new generation of ionizable cationic lipids was greatly improved as compared to systems made with earlier generations of lipids, a recent study suggested that the intracellular release of siRNA from the current LNP-siRNA systems is a highly inefficient process. Following uptake of LNP-siRNA into the cell via endocytosis, only 1--2% of the total siRNA is released into the cytosol within a small window of time when LNP-siRNA accumulate in a specific endocytic compartment with both early and late endosomal characteristics ([@bib48]). In addition, the authors did not detect any major disruption of the endosomal membrane. Another recent report on the intracellular trafficking of LNP-siRNA systems revealed that approximately 70% of internalized particles eventually exits the cell through a recycling mechanism dependent on the protein Niemann-Pick Type C-1 (NPC1) ([@bib124]). Cells lacking the NPC1 gene were shown to have reduced endosomal recycling activities between late endosomes or lysosomes to the extracellular medium. As a result, these cells retain more LNP-siRNA following endocytosis and show more potent gene silencing than wild-type cells. It is therefore possible to improve the gene silencing potency of LNP-siRNA systems by manipulating the endocytic pathways to increase the intracellular accumulation of LNP-siRNA and/or the release of siRNA into the cytosol. Coincidentally, cellular entry of Ebola virus also requires functional NPC1 and treatment of cells with small molecular inhibitors of NPC1 greatly attenuates infections by the virus ([@bib23]; [@bib32]). Such small molecule inhibitors of NPC1 can be used in conjunction with LNP-siRNA to inhibit LNP-siRNA recycling and thus enhance the bioavailability of the internalized siRNA and gene silencing potency.

Incorporation of metallic nanoparticles in LNP-siRNA systems may offer an attractive method to disrupt the endosomal membrane. By exciting the metallic nanoparticle embedded in a lipid membrane through light radiation or a magnetic field, it is possible to increase the temperature of the lipid membrane to its gel-to-liquid crystal phase transition temperature (T~M~) at which the permeability of the membrane is the greatest. Liposomes with gold nanoparticles embedded in their membrane have been shown to release their aqueous content following irradiation with ultra-violet light ([@bib113]). In addition to gold, other metallic nanoparticles such as iron oxide were utilized in generating thermo-sensitive liposomes ([@bib7]). Formulations of gold nanoparticles with liposome have been prepared by several different methods: (1) reverse-phase evaporation with gold nanoparticles suspended in the organic phase ([@bib61]; [@bib113]); (2) physical adsorption of gold nanoparticles onto the surface of liposomes ([@bib79]); (3) postinsertion of gold nanoparticle-conjugated phospholipids onto preformed liposomes ([@bib27]) and (4) embedding gold nanoparticle in a dry lipid film followed by hydration ([@bib114]). Recently, our laboratory has demonstrated encapsulation of gold nanoparticles in LNP by mixing the commonly used lipids in LNP-siRNA formulation with commercially available negatively charged gold nanoparticles in a microfluidic mixer (unpublished). This method is straightforward as the ionizable cationic lipids bind to the negatively charged gold nanoparticles in a manner similar to the encapsulation of siRNA. Using the same method, LNP encapsulation of iron oxide nanoparticles is potentially possible when they are modified with functional groups such as carboxylic acids or silica to render their surface negatively charged ([@bib82]). A thermo-sensitive LNP-siRNA system can be generated by co-encapsulating metallic nanoparticles with siRNA using ionizable cationic lipids. Enhanced release of siRNA following cellular uptake may be made possible by excitation of cells or tissues with ultra-violet light or alternating magnetic field to generate enough heat to disrupt or permeabilize the endosomal membrane.

In addition to the potential benefit of enhancing endosomal release of siRNA, metallic nanoparticles co-encapsulated with siRNA in the same LNP system can also serve as a contrast agent for bioimaging. Gold nanoparticles, a good absorber of X-ray radiation, have been shown to provide therapeutic effects in tumor-bearing mice after radiotherapy and enhance contrast of tumors during X-ray imaging ([@bib57]; [@bib56]; [@bib58]). However, the use of gold nanoparticles in radiation medicine or bioimaging suffers from poor accumulation of gold nanoparticles in tumors and rapid excretion through the kidneys following i.v. injection ([@bib57]). Thus, a LNP carrier system has the potential to improve the accumulation of the metallic nanoparticle to tumor sites by the aforementioned EPR effect. Co-encapsulation of siRNA with metallic nanoparticles can therefore generate an LNP system with dual functionality that allows both bioimaging of the tumor and silencing of the target gene for therapeutic purposes. It is anticipated that such "theranostic" system would have tremendous impact in the biomedical applications of LNP technologies.

5.2. Delivery of Other Nucleic Acids {#s0065}
------------------------------------

The ionizable cationic lipid-based encapsulation technology for siRNA described above is fully applicable to other nucleic acid polymers such as plasmids and mRNA. A major challenge for LNP-plasmid systems is sufficient target gene expression since the nuclear envelope remains the barrier to the translocation of plasmid DNA into the nucleus. Efficient transgene expression is usually only observed in rapidly dividing cell where the nuclear envelope disintegrates during mitosis allowing the plasmid DNA to enter the nucleus ([@bib11]; [@bib108]). In contrast, mRNA-LNP systems eliminate the need for nuclear translocation for gene expression ([@bib59]; [@bib170]). It has been shown that mRNA delivered by electroporation can result in the expression of target gene ([@bib179]). The therapeutic potential of mRNA was demonstrated by the fact that chemically modified mRNA can mediate the expression of the target protein, SP-B, in the lungs following intratracheal administration in SP-B deficient mice ([@bib80]). However, many tissues are inaccessible by local administration and the LNP-mRNA systems should allow systemic delivery with particular potency for tissues such as the liver (hepatocytes). Recently, it has been demonstrated that chemically modified mRNA condensed by protamine can be encapsulated inside of preformed cationic vesicles ([@bib152], [@bib153]). The microfluidic mixing method presented previously would eliminate the need for nucleic acid-condensing agents such as protamine and the need for the time-consuming extrusion process. As LNP-mRNA systems produced by microfluidic mixing would contain the same lipid components as used for the delivery of siRNA, it is expected that these LNP-mRNA would display biodistribution and pharmacokinetic properties similar to that of LNP-siRNA systems. The ability to systemically deliver mRNA has considerable potential for the treatment of cancer and a variety of genetic disorders.

Another genetic material that can benefit from lipid-based delivery for therapeutic purposes is the recently discovered clustered, regularly interspaced, short palindromic repeats (CRISPR). CRISPR were originally discovered in *Escherichia coli* and was subsequently recognized as an important adaptive immunity pathway found in bacteria and archaea ([@bib68]; [@bib100]). The mechanism of bacterial adaptive immunity by CRISPR has been reviewed extensively elsewhere ([@bib100]; [@bib123]; [@bib136]; [@bib154]; [@bib157]). Recent interests in CRISPR technology stemmed from the possibility of using CRISPR to modify genes in order to tackle human diseases. CRISPR, along with the endonuclease CRISPR-associated protein 9 (Cas9), facilitate genome editing by introducing double-strand breaks at a specific genetic locus that has sequence complementary to the guide RNA (gRNA) ([@bib71], [@bib72]). A gene can therefore be deleted or replaced using this novel technology. The CRISPR system has been used to produce genetically modified animals from numerous species, including fruit fly, zebrafish, rabbit, rat and mouse (reviewed in [@bib125]). Genetically modified mice have been produced by injecting mRNA encoding the endonuclease Cas9, along with guide RNA (gRNA) targeting the gene to be modified, into mouse embryos ([@bib152], [@bib153]). The CRISPR system can also be used to correct disease-causing mutations. Cataract-free mice have been generated by injecting Cas9 mRNA and gRNA targeting the mutated *Crygc* gene locus into mouse zygotes followed by implantation in surrogate female mice ([@bib160]). Also, mutated cystic fibrosis transmembrane conductor receptor (CFTR) from the intestinal stem cells of cystic fibrosis patients has been corrected by the CRISPR/Cas system using gRNA targeting the mutated *CFTR* locus along with a plasmid DNA encoding the correct *CFTR* sequence as a template for homology-directed repair ([@bib129]). These preliminary examples support CRISPR-mediated genetic modifications as novel strategies to treat genetic diseases.

Proper genetic modification by CRISPR requires at least two components to be introduced to the target cells: first, the gRNA specific to the genetic locus to be modified; and second, the Cas9 endonuclease, which is usually introduced as a plasmid vector or mRNA. If the cell to be modified contains a homozygous mutation of the gene, an additional plasmid encoding the correct version of the gene is necessary in order to facilitate homology-directed repair of the mutation. It is obvious that all these nucleic acids require an efficient method to enter the target cells. The examples of CRISPR-mediated genetic modifications mentioned above used either commercially available transfection reagent, viral vectors or direct injection of CRISPR components into the target cells, which all have inferior in vivo performances as compared to lipid-based delivery systems. It is clear that our understanding of CRISPR/Cas system is still at the early stage; however, numerous companies have begun aggressive programs to develop research tools for the CRISPR field (reviewed in [@bib10]). The race for the first CRISPR-based therapeutic for genetic diseases are currently underway and much like the development of siRNA-based drugs 10 years ago, the development of an effective delivery system for CRISPR components will be the key to this race. Based on its proven track record in nucleic acid delivery, it is possible that lipid-based systems will be at the forefront of this CRISPR technology. It remains to be seen whether CRISPR technologies will enjoy as much success as siRNA has in the clinic and it is certain that we will see many innovations in both formulation method and delivery material for CRISPR in the near future.
